Cover Image

Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study

Background: Chemotherapy with lomustine is widely considered as standard treatment option for progressive glioblastoma. The value of adding radiotherapy to second-line chemotherapy is not known. Methods: EORTC-2227-BTG (LEGATO, NCT05904119) is an investigator-initiated, pragmatic (PRECIS-2 score: 34...

Full description

Saved in:
Bibliographic Details
Main Authors: Preusser, Matthias (Author) , Kazda, Tomáš (Author) , Le Rhun, Emilie (Author) , Sahm, Felix (Author) , Smits, Marion (Author) , Gempt, Jens (Author) , Koekkoek, Johan AF (Author) , Monti, Angelo F. (Author) , Csanadi, Marcell (Author) , Pitter, János György (Author) , Bulbek, Helen (Author) , Fournier, Beatrice (Author) , Quoilin, Caroline (Author) , Gorlia, Thierry (Author) , Weller, Michael (Author) , Minniti, Giuseppe (Author)
Format: Article (Journal)
Language:English
Published: 07 June 2024
In: Trials
Year: 2024, Volume: 25, Pages: 1-10
ISSN:1468-6694
DOI:10.1186/s13063-024-08213-7
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13063-024-08213-7
Get full text
Author Notes:Matthias Preusser, Tomáš Kazda, Emilie Le Rhun, Felix Sahm, Marion Smits, Jens Gempt, Johan AF Koekkoek, Angelo F. Monti, Marcell Csanadi, János György Pitter, Helen Bulbek, Beatrice Fournier, Caroline Quoilin, Thierry Gorlia, Michael Weller, Giuseppe Minniti, and on behalf of the European Organisation for Research
Description
Summary:Background: Chemotherapy with lomustine is widely considered as standard treatment option for progressive glioblastoma. The value of adding radiotherapy to second-line chemotherapy is not known. Methods: EORTC-2227-BTG (LEGATO, NCT05904119) is an investigator-initiated, pragmatic (PRECIS-2 score: 34 out of 45), randomized, multicenter phase III trial in patients with first progression of glioblastoma. A total of 411 patients will be randomized in a 1:1 ratio to lomustine (110 mg/m2 every 6 weeks) or lomustine (110 mg/m2 every 6weeks) plus radiotherapy (35 Gy in 10 fractions). Main eligibility criteria include histologic confirmation of glioblastoma, isocitrate dehydrogenase gene (IDH) wild-type per WHO 2021 classification, first progression at least 6 months after the end of prior radiotherapy, radiologically measurable disease according to RANO criteria with a maximum tumor diameter of 5 cm, and WHO performance status of 0–2. The primary efficacy endpoint is overall survival (OS) and secondary endpoints include progression-free survival, response rate, neurocognitive function, health-related quality of life, and health economic parameters. LEGATO is funded by the European Union’s Horizon Europe Research program, was activated in March 2024 and will enroll patients in 43 sites in 11 countries across Europe with study completion projected in 2028. Discussion: EORTC-2227-BTG (LEGATO) is a publicly funded pragmatic phase III trial designed to clarify the efficacy of adding reirradiation to chemotherapy with lomustine for the treatment of patients with first progression of glioblastoma. Trial registration: ClinicalTrials.gov NCT05904119. Registered before start of inclusion, 23 May 2023
Item Description:Gesehen am 02.12.20224
Physical Description:Online Resource
ISSN:1468-6694
DOI:10.1186/s13063-024-08213-7

Similar Items